Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of...
Gespeichert in:
| Veröffentlicht in: | Journal for immunotherapy of cancer 2015-12, Vol.3 (1), p.51-51, Article 51 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 51 |
| container_title | Journal for immunotherapy of cancer |
| container_volume | 3 |
| creator | Moon, Yong Wha Hajjar, Joud Hwu, Patrick Naing, Aung |
| description | Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development. |
| doi_str_mv | 10.1186/s40425-015-0094-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4678703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468899813</galeid><sourcerecordid>A468899813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c591t-b19f709c792e363ae8f9cc4639a5bac74eee4e479e4364836e7cc618c2e776ae3</originalsourceid><addsrcrecordid>eNptkl1rFDEUhoMotqz9Ad7IgCBeODUnyeQDQSjFLyh4U69DNntmJmUmWScz1f33ZtladkVCSEie9z2cw0vIS6CXAFq-z4IK1tQUyqZG1OYJOWe0gRoEk0-P7mfkIuc7SilQzrXWz8kZk1IJAXBOPty6qcM5xK6ae6xC3KQB3RgiVuwdrzch_d51GF3Gauvm_pfbFabyLnqcXpBnrRsyXjycK_Lj86fb66_1zfcv366vbmrfGJjrNZhWUeOVYcgld6hb472Q3Lhm7bwSiChQKIOCS6G5ROW9BO0ZKiUd8hX5ePDdLusRNx7jPLnBbqcwumlnkwv29CeG3nbp3gqptCpNr8jbB4Mp_Vwwz3YM2eMwuIhpyRZUU2apmRAFff0PepeWKZb2LJNcAzDFjqjODWhDbFOp6_em9kpIrY3RsC97-R-qrA2OwaeIbSjvJ4I3R4Ie3TD3OQ3LHFLMpyAcQD-lnCdsH4cB1O7TYQ_psCUddp8Oa4rm1fEUHxV_s8D_AOjvshQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638112724</pqid></control><display><type>article</type><title>Targeting the indoleamine 2,3-dioxygenase pathway in cancer</title><source>BMJ Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Springer Nature OA Free Journals</source><creator>Moon, Yong Wha ; Hajjar, Joud ; Hwu, Patrick ; Naing, Aung</creator><creatorcontrib>Moon, Yong Wha ; Hajjar, Joud ; Hwu, Patrick ; Naing, Aung</creatorcontrib><description>Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.</description><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1186/s40425-015-0094-9</identifier><identifier>PMID: 26674411</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antigens ; Autoimmune diseases ; Breast cancer ; Cancer ; Colorectal cancer ; Endometrial cancer ; Enzymes ; Gene expression ; Immune response ; Immune system ; Immunotherapy ; Kinases ; Leukemia ; Lung cancer ; Lymphatic system ; Lymphocytes ; Medical prognosis ; Melanoma ; Ovarian cancer ; Proteins ; Review ; Tumors</subject><ispartof>Journal for immunotherapy of cancer, 2015-12, Vol.3 (1), p.51-51, Article 51</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>2015 Moon et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Moon et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c591t-b19f709c792e363ae8f9cc4639a5bac74eee4e479e4364836e7cc618c2e776ae3</citedby><cites>FETCH-LOGICAL-c591t-b19f709c792e363ae8f9cc4639a5bac74eee4e479e4364836e7cc618c2e776ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678703/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678703/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,723,776,780,788,860,881,27899,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26674411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moon, Yong Wha</creatorcontrib><creatorcontrib>Hajjar, Joud</creatorcontrib><creatorcontrib>Hwu, Patrick</creatorcontrib><creatorcontrib>Naing, Aung</creatorcontrib><title>Targeting the indoleamine 2,3-dioxygenase pathway in cancer</title><title>Journal for immunotherapy of cancer</title><addtitle>J Immunother Cancer</addtitle><description>Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.</description><subject>Analysis</subject><subject>Antigens</subject><subject>Autoimmune diseases</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Colorectal cancer</subject><subject>Endometrial cancer</subject><subject>Enzymes</subject><subject>Gene expression</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Ovarian cancer</subject><subject>Proteins</subject><subject>Review</subject><subject>Tumors</subject><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkl1rFDEUhoMotqz9Ad7IgCBeODUnyeQDQSjFLyh4U69DNntmJmUmWScz1f33ZtladkVCSEie9z2cw0vIS6CXAFq-z4IK1tQUyqZG1OYJOWe0gRoEk0-P7mfkIuc7SilQzrXWz8kZk1IJAXBOPty6qcM5xK6ae6xC3KQB3RgiVuwdrzch_d51GF3Gauvm_pfbFabyLnqcXpBnrRsyXjycK_Lj86fb66_1zfcv366vbmrfGJjrNZhWUeOVYcgld6hb472Q3Lhm7bwSiChQKIOCS6G5ROW9BO0ZKiUd8hX5ePDdLusRNx7jPLnBbqcwumlnkwv29CeG3nbp3gqptCpNr8jbB4Mp_Vwwz3YM2eMwuIhpyRZUU2apmRAFff0PepeWKZb2LJNcAzDFjqjODWhDbFOp6_em9kpIrY3RsC97-R-qrA2OwaeIbSjvJ4I3R4Ie3TD3OQ3LHFLMpyAcQD-lnCdsH4cB1O7TYQ_psCUddp8Oa4rm1fEUHxV_s8D_AOjvshQ</recordid><startdate>20151215</startdate><enddate>20151215</enddate><creator>Moon, Yong Wha</creator><creator>Hajjar, Joud</creator><creator>Hwu, Patrick</creator><creator>Naing, Aung</creator><general>BioMed Central Ltd</general><general>BMJ Publishing Group LTD</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151215</creationdate><title>Targeting the indoleamine 2,3-dioxygenase pathway in cancer</title><author>Moon, Yong Wha ; Hajjar, Joud ; Hwu, Patrick ; Naing, Aung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c591t-b19f709c792e363ae8f9cc4639a5bac74eee4e479e4364836e7cc618c2e776ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Antigens</topic><topic>Autoimmune diseases</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Colorectal cancer</topic><topic>Endometrial cancer</topic><topic>Enzymes</topic><topic>Gene expression</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Ovarian cancer</topic><topic>Proteins</topic><topic>Review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moon, Yong Wha</creatorcontrib><creatorcontrib>Hajjar, Joud</creatorcontrib><creatorcontrib>Hwu, Patrick</creatorcontrib><creatorcontrib>Naing, Aung</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moon, Yong Wha</au><au>Hajjar, Joud</au><au>Hwu, Patrick</au><au>Naing, Aung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting the indoleamine 2,3-dioxygenase pathway in cancer</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><addtitle>J Immunother Cancer</addtitle><date>2015-12-15</date><risdate>2015</risdate><volume>3</volume><issue>1</issue><spage>51</spage><epage>51</epage><pages>51-51</pages><artnum>51</artnum><issn>2051-1426</issn><eissn>2051-1426</eissn><abstract>Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26674411</pmid><doi>10.1186/s40425-015-0094-9</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2051-1426 |
| ispartof | Journal for immunotherapy of cancer, 2015-12, Vol.3 (1), p.51-51, Article 51 |
| issn | 2051-1426 2051-1426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4678703 |
| source | BMJ Open Access Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Springer Nature OA Free Journals |
| subjects | Analysis Antigens Autoimmune diseases Breast cancer Cancer Colorectal cancer Endometrial cancer Enzymes Gene expression Immune response Immune system Immunotherapy Kinases Leukemia Lung cancer Lymphatic system Lymphocytes Medical prognosis Melanoma Ovarian cancer Proteins Review Tumors |
| title | Targeting the indoleamine 2,3-dioxygenase pathway in cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A51%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20the%20indoleamine%202,3-dioxygenase%20pathway%20in%20cancer&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Moon,%20Yong%20Wha&rft.date=2015-12-15&rft.volume=3&rft.issue=1&rft.spage=51&rft.epage=51&rft.pages=51-51&rft.artnum=51&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1186/s40425-015-0094-9&rft_dat=%3Cgale_pubme%3EA468899813%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638112724&rft_id=info:pmid/26674411&rft_galeid=A468899813&rfr_iscdi=true |